Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report

References

• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa1810865
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Couraud S, Souquet P-J, Paris C, et al. BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. Eur Respir J. 2015;45(5):1403–1414. doi:10.1183/09031936.00097214
   PubMed Web of Science ®Google Scholar
• Besse B, Adjei A, Baas P, et al. 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475–1484. doi:10.1093/annonc/mdu123
   PubMed Web of Science ®Google Scholar
• Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850–859. doi:10.1158/2159-8290.CD-15-0285
   PubMed Web of Science ®Google Scholar
• Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11(9):1493–1502. doi:10.1016/j.jtho.2016.06.004
   PubMed Web of Science ®Google Scholar
• Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. PLoS One. 2014;9(6):e99399. doi:10.1371/journal.pone.0099399
   PubMed Web of Science ®Google Scholar
• Tong JH, Yeung SF, Chan AWH, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22(12):3048–3056. doi:10.1158/1078-0432.CCR-15-2061
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–1043. doi:10.1126/science.1141478
   PubMed Web of Science ®Google Scholar
• Spigel DR, Edelman MJ, O’Byrne K, et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METlung. J Clin Oncol. 2017;35(4):412–420. doi:10.1200/JCO.2016.69.2160
   PubMed Web of Science ®Google Scholar
• Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression. J Clin Oncol. 2016;34(7):721–730. doi:10.1200/JCO.2015.63.4600
   PubMed Web of Science ®Google Scholar
• Paik PK, Drilon A, Fan P-D, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842–849. doi:10.1158/2159-8290.CD-14-1467
   PubMed Web of Science ®Google Scholar
• Heist RS, Shim HS, Gingipally S, et al. MET exon 14 skipping in non-small cell lung cancer. Oncologist. 2016;21(4):481–486. doi:10.1634/theoncologist.2015-0510
   PubMed Web of Science ®Google Scholar
• Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34(8):794–802. doi:10.1200/JCO.2015.62.0674
   PubMed Web of Science ®Google Scholar
• Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681–1690. doi:10.1093/annonc/mdu145
   PubMed Web of Science ®Google Scholar
• Jin Y, Sun P-L, Kim H, et al. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas. Ann Surg Oncol. 2014;21(2):621–628. doi:10.1245/s10434-013-3355-1
   PubMed Web of Science ®Google Scholar
• Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31(32):4105–4114. doi:10.1200/JCO.2012.47.4189
   PubMed Web of Science ®Google Scholar
• Kowalczuk O, Kozlowski M, Niklinska W, Kisluk J, Niklinska BJ, Niklinski J. Increased MET gene copy number but not mRNA level predicts postoperative recurrence in patients with non-small cell lung cancer. Transl Oncol. 2014;7(5):605–612. doi:10.1016/j.tranon.2014.08.002
   PubMed Web of Science ®Google Scholar
• Jurmeister P, Lenze D, Berg E, et al. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Lung Cancer. 2015;87(2):122–129. doi:10.1016/j.lungcan.2014.11.018
   PubMed Web of Science ®Google Scholar
• Noro R, Seike M, Zou F, et al. MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation. BMC Cancer. 2015;15:31. doi:10.1186/s12885-015-1019-1
   PubMed Web of Science ®Google Scholar
• Weingertner N, Meyer N, Voegeli A-C, et al. Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification. Pathology. 2015;47(4):320–328. doi:10.1097/PAT.0000000000000269
   PubMed Web of Science ®Google Scholar
• Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5Suppl):e278S–e313S. doi:10.1378/chest.12-2359
   PubMedGoogle Scholar
• Pisters KMW, Evans WK, Azzoli CG, et al. Cancer care Ontario and American society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol. 2007;25(34):5506–5518. doi:10.1200/JCO.2007.14.1226
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. Arch Pathol Lab Med. 2018;142(3):321–346. doi:10.5858/arpa.2017-0388-CP
   PubMed Web of Science ®Google Scholar
• Maesako Y, Okumura A, Takeoka K, et al. Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia. Leukemia. 2014;28(9):1935–1937. doi:10.1038/leu.2014.166
   PubMed Web of Science ®Google Scholar
• Maxson JE, Davare MA, Luty SB, et al. Therapeutically targetable ALK mutations in leukemia. Cancer Res. 2015;75(11):2146–2150. doi:10.1158/0008-5472.CAN-14-1576
   PubMed Web of Science ®Google Scholar
• Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834–848. doi:10.1038/nrm3012
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103. doi:10.1038/nrc3205
   PubMed Web of Science ®Google Scholar
• Sierra JR, Tsao M-S. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(1 Suppl):S21–35. doi:10.1177/1758834011422557
   PubMedGoogle Scholar
• Feng Y, Thiagarajan PS, Ma PC. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol. 2012;7(2):459–467. doi:10.1097/JTO.0b013e3182417e44
   PubMed Web of Science ®Google Scholar
• Recondo G, Che J, Jänne PA, Awad MM. Targeting MET dysregulation in cancer. Cancer Discov. 2020;10(7):922–934. doi:10.1158/2159-8290.CD-19-1446
   PubMed Web of Science ®Google Scholar
• Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA. 1997;94(21):11445–11450. doi:10.1073/pnas.94.21.11445
   PubMed Web of Science ®Google Scholar
• Ma PC. MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker. Cancer Discov. 2015;5(8):802–805. doi:10.1158/2159-8290.CD-15-0769
   PubMed Web of Science ®Google Scholar
• Baldacci S, Kherrouche Z, Descarpentries C, et al. [MET exon 14 splicing sites mutations: a new therapeutic opportunity in lung cancer]. Rev Mal Respir. 2018;35(8):796–812. French. doi:10.1016/j.rmr.2018.01.011
   PubMed Web of Science ®Google Scholar
• Huang C, Zou Q, Liu H, et al. Management of non-small cell lung cancer patients with MET exon 14 skipping mutations. Curr Treat Options Oncol. 2020;21(4):33. doi:10.1007/s11864-020-0723-5
   PubMed Web of Science ®Google Scholar
• Cui JJ, Tran-Dubé M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54(18):6342–6363. doi:10.1021/jm2007613
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi:10.1056/NEJMoa1214886
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non–small-cell lung cancer. J Clin Oncol. 2013;31(8):1097–1104. doi:10.1200/JCO.2012.42.9829
   PubMed Web of Science ®Google Scholar
• Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47–51. doi:10.1038/s41591-019-0716-8
   PubMed Web of Science ®Google Scholar
• Wolf J, Seto T, Han J-Y, et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY Mono-1 Study. JCO. 2019;37(15_suppl):9004. doi:10.1200/JCO.2019.37.15_suppl.9004
   Google Scholar
• Paik PK, Veillon R, Cortot AB, et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. J Clin Oncol. 2020. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9005.
   PubMedGoogle Scholar
• Lu S, Fang J, Li X, et al. Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). JCO. 2020;38(15_suppl):9519. doi:10.1200/JCO.2020.38.15_suppl.9519
   Web of Science ®Google Scholar
• Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931–943. doi:10.1056/NEJMoa2004407
   PubMed Web of Science ®Google Scholar
• Traslazionale FR. Phase II single arm study with CABozantinib in non-small cell lung cancer patients with MET deregulation. clinicaltrials.gov; 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03911193. Accessed August 5, 2020.
   Google Scholar
• Mirati Therapeutics Inc. Phase 2, parallel-arm study of MGCD265 in patients with locally advanced or metastatic non-small cell lung cancer with activating genetic alterations in mesenchymal-epithelial transition factor. clinicaltrials.gov; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02544633. Accessed August 5, 2020.
   Google Scholar
• Guo R, Offin M, Brannon AR, et al. MET inhibitor resistance in patients with MET exon 14-altered lung cancers. JCO. 2019;37(15_suppl):9006. doi:10.1200/JCO.2019.37.15_suppl.9006
   Google Scholar
• Engstrom LD, Aranda R, Lee M, et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring met exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models. Clin Cancer Res. 2017;23(21):6661–6672. doi:10.1158/1078-0432.CCR-17-1192
   PubMed Web of Science ®Google Scholar
• Klempner SJ, Borghei A, Hakimian B, Ali SM, Ou S-HI. Intracranial activity of cabozantinib in MET exon 14-positive NSCLC with brain metastases. J Thorac Oncol. 2017;12(1):152–156. doi:10.1016/j.jtho.2016.09.127
   PubMed Web of Science ®Google Scholar